Cell interactions of the pancreatic cancer microenvironment (WP5284)

Homo sapiens

The molecular interactions of different cells in the pancreatic cancer tumor microenvironment (TME). Pancreatic cancer cells have developed various ways of evading and manipulating the immune system, and the TME plays an essential role in this. Various molecular interactions are involved in the interactions between cells in the TME.


Isabel Wassink and Martina Summer-Kutmon


last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited By

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.


Homo sapiens




Disease Ontology

pancreatic cancer

Pathway Ontology

pancreatic cancer pathway


Label Type Compact Identifier Comment
CD86 GeneProduct ensembl:ENSG00000114013
CTLA4 GeneProduct ensembl:ENSG00000163599
CCR5 GeneProduct ensembl:ENSG00000160791
FASLG GeneProduct ensembl:ENSG00000117560
CXCL12 GeneProduct ensembl:ENSG00000107562
CCR2 GeneProduct ensembl:ENSG00000121807
CSF2RA GeneProduct ensembl:ENSG00000198223
CXCR3 GeneProduct ensembl:ENSG00000186810
FAS GeneProduct ensembl:ENSG00000026103
TGFB1 GeneProduct ensembl:ENSG00000105329
IFITM2 GeneProduct ensembl:ENSG00000185201
BAG3 GeneProduct ensembl:ENSG00000151929
HLA-DRB1 GeneProduct ensembl:ENSG00000196126
LAG3 GeneProduct ensembl:ENSG00000089692
NRP1 GeneProduct ensembl:ENSG00000099250
CSF1 GeneProduct ensembl:ENSG00000184371
CXCL10 GeneProduct ensembl:ENSG00000169245
CSF1R GeneProduct ensembl:ENSG00000182578
TRA GeneProduct ncbigene:6955
CCL5 GeneProduct ensembl:ENSG00000271503
HLA-DRA GeneProduct ensembl:ENSG00000204287
CCR2 GeneProduct ensembl:ENSG00000121807
CD80 GeneProduct ensembl:ENSG00000121594
CCL2 GeneProduct ensembl:ENSG00000108691
CCL5 GeneProduct ensembl:ENSG00000271503
KDR GeneProduct ensembl:ENSG00000128052
VEGFA GeneProduct ensembl:ENSG00000112715
CXCR4 GeneProduct ensembl:ENSG00000121966
CSF2 GeneProduct ensembl:ENSG00000164400
VEGFA GeneProduct ensembl:ENSG00000112715
HLA-DRB1 GeneProduct ensembl:ENSG00000196126
HLA-DRA GeneProduct ensembl:ENSG00000204287
TRB GeneProduct ncbigene:6957
TRA GeneProduct ncbigene:6955
TRB GeneProduct ncbigene:6957
LAG3 GeneProduct ensembl:ENSG00000089692


  1. BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. Rosati A, Basile A, D’Auria R, d’Avenia M, De Marco M, Falco A, et al. Nat Commun. 2015 Nov 2;6:8695. PubMed Europe PMC Scholia
  2. VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature. Costache MI, Ioana M, Iordache S, Ene D, Costache CA, Săftoiu A. Rom J Intern Med. 2015;53(3):199–208. PubMed Europe PMC Scholia
  3. Novel regulatory role of neuropilin-1 in endothelial-to-mesenchymal transition and fibrosis in pancreatic ductal adenocarcinoma. Matkar PN, Singh KK, Rudenko D, Kim YJ, Kuliszewski MA, Prud’homme GJ, et al. Oncotarget. 2016 Oct 25;7(43):69489–506. PubMed Europe PMC Scholia
  4. LAG3 (CD223) as a cancer immunotherapy target. Andrews LP, Marciscano AE, Drake CG, Vignali DAA. Immunol Rev. 2017 Mar;276(1):80–96. PubMed Europe PMC Scholia
  5. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. Balachandran VP, Beatty GL, Dougan SK. Gastroenterology. 2019 May;156(7):2056–72. PubMed Europe PMC Scholia
  6. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Fan JQ, Wang MF, Chen HL, Shang D, Das JK, Song J. Mol Cancer. 2020 Feb 15;19(1):32. PubMed Europe PMC Scholia